Abstract: The development of an implantable system designed to deliver drug doses in a controlled manner over an extended time period is reported. Key performance parameters are the physical size, the power consumption and also the ability to perform wireless communications to enable the system to be externally controlled and interrogated. The system has been designed to facilitate wireless power transfer, which is very important for miniaturisation as it removes the need for a battery.
Introduction
The ability to deliver metered doses of a drug to a localised site is increasingly the focus of much micro-and nanosystems research. By releasing drugs in a controlled manner at a required site, microdrug delivery systems can reduce the negative side effects associated with systemic medication. In addition, drug doses can be delivered to the disease location in a highly concentrated form that would be damaging to the body if delivered in a traditional manner.
The specific objective of the work described was to investigate the feasibility of implementing an implantable microelectro-mechanical systems (MEMS) drug delivery system suitable for intraocular applications. The device would be permanently implanted and capable of delivering daily doses of a drug for up to 1 year. Power and communication with the device would be provided by a wireless link that would only be activated when required by the system, thereby reducing power and exposure to radio frequency (RF) radiation. The single operation to implant the device would obviate the need for regular, painful and invasive injections.
Background
Micromachined drug release systems come in two main forms: passive devices where the point is to control the rate of diffusion of the drug being delivered, and active devices where a dose of the drug can be released at a controlled time, usually with an external trigger. Passive drug delivery devices are either large structures implanted at the required position or smaller objects that can be injected and then travel to the correct position. Examples of devices using silicon structures to provide delayed drug release include chips with nanoengineered channels that enable slow, zero-order diffusion [1] and porous silicon pellets coated in a drug [2] . The porous silicon is extremely interesting because it is biodegradable, in addition to being biocompatible, and this means that it is suitable for other medical applications such as a scaffold for bone growth.
Active drug release systems include micropumps and valves using shape memory alloys [3] , [4] , silicon piezoelectric micropumps [5] , transdermal microneedles [6] and microreservoir chips, where the drug is released by melting a metal membrane [7] .
The drug delivery system used here is based on a device reported in Nature [8] , consisting of a microarray of sealed silicon reservoirs containing the required drug(s), which can be released electrochemically by the removal of a gold cap. Fig. 1 illustrates this concept. More recently, the company formed to commercialise the MIT work, MicroCHIPS, have presented results of an in vivo trial using their implantable drug release system [9] . Their device consists of a drug delivery chip with 100 cavities packaged along with a battery, control electronics and wireless communications. This device uses a different release mechanism, by which a thin metal membrane sealing the drug cavity is removed electrothermally as described in [10] . In this example, the complete device is 5 cm long and 4 cm wide, which makes it unsuitable for implantation into the posterior cavity of the eye.
In a silicon drug delivery device as originally envisaged in [8] , the gold cap over the reservoir forms the anode of an electrochemical cell. In the presence of a solution containing chloride ions, the gold anode reacts to form gold(III) chloride complexes that are soluble in an aqueous electrolyte [11] . There have been some concerns about the toxicity of gold(III) complexes, but in vivo studies based on the use of gold implants have only shown significant immune reactions when the dosage was .250 mg [12] . The amount of gold converted when opening one of these devices is significantly lower, of the order of 10 ng.
The initial study found that the gold dissolution reaction occurred when a voltage of þ1.04 V against saturated calomel reference electrode (SCE) was applied to the anode when immersed in 0.1 M phosphate-buffered saline (PBS). When this voltage is applied for 10-30 s, the cap is removed and the drug in the reservoir diffuses out into the electrolyte over the space of 1 -2 h. In order to ensure that gold is only removed from the desired areas, the surface is covered with a passivation layer of silicon dioxide, or nitride, and patterned to expose certain areas to the electrolyte. Fig. 2 shows a block diagram of an implantable drug delivery system that consists of three main parts: the drug delivery chip, the control circuitry to facilitate the release of drugs from the cavities and the RF/communications system to transfer power and data. Integration of cell addressing onto the drug delivery chip, reduction of control circuitry to a single IC and the use of wireless power transfer without a battery will all help to reduce the size of the system; the ultimate aim is a complete implantable device with dimensions of 5 Â 5 Â 5 mm or less. It is this combination of miniaturisation and integration, coupled with the addition of wireless power transfer, that distinguishes the drug delivery system described in this article from systems described in the literature.
System description

Drug delivery chip
The drug delivery chip comprises an array of cavities ( Fig.1 shows a cross-section through a single cavity), each of which can be individually activated [13] . When the number of reservoirs is small, it is feasible for each gold cap to be individually wired to the control system. However, as the number of cavities increases, a row and column addressing system, using on-chip complementary metal oxide semiconductor (CMOS) circuitry, becomes essential to reduce the number of connections.
Control circuitry
When the system is activated, the control chip needs to determine which of the cavities will be opened next and then apply the correct voltage signal to the drug delivery chip in order to release the dose of drug. In the absence of on-board memory, the control chip must test the status of each cell on the drug delivery chip and determine which cavities have already been opened. There are many aspects of the control circuitry that require careful attention, not least of which is a fail-safe system that ensures that under no circumstances can multiple cavities be opened simultaneously.
RF power and communications
The RF power system receives power wirelessly from an external base station and converts this into the voltages required by the control and drug delivery chips. If two-way communication is required, this system also needs to transmit information about the status of the system back to the base station. For example, this could include information about which cavities on the drug delivery chip have been opened and the readings of any on-board sensor measuring drug concentration or other environmental parameters.
Design considerations
Consideration must be given to the method of fabricating silicon cavities as this impacts on both the number and the volume of the reservoirs. The gold cap on the reservoir has an important role as it seals one end of the cavity. It is also the most fragile part of the structure. Therefore a robust method of protecting the caps during processing is essential in order to achieve acceptable yields for these devices.
Once the cavities have been fabricated, they must be filled and sealed, and a wide range of different techniques for achieving this have been assessed. The filled devices must then be packaged, which requires electrical connections that are waterproof, bearing in mind that the gold caps over the reservoirs must be exposed to the electrolyte.
Finally, the correct electrical excitation required to quickly and reliably open the gold caps must be determined, as this places limits on the systems used to power and control the device.
Fabrication technology
This section describes the methods used to fabricate the initial prototype drug delivery devices. These are fully wired structures that do not require any on-chip electronics. The process flow is shown in Fig. 3 .
Cavity construction
The bulk etching or micromachining of silicon is a standard technology in MEMS fabrication [14] . Isotropic etch processes remove exposed silicon equally quickly in all directions giving a rounded hole. Anisotropic etches can be split into two groups depending on whether a wet or dry process is used. Wet anisotropic etches tend to preferentially remove silicon in certain crystal planes and will be discussed in more detail later in this document. Dry anisotropic etch processes can produce a number of different etch profiles but the most common is the Bosch process, which is capable of producing high aspect ratio cavities with almost vertical sidewalls [15] .
Anisotropic wet silicon etch processes remove (1 1 1) oriented silicon planes significantly more slowly than the other crystal planes. As a result, cavities fabricated using these methods will have smooth, well-defined (1 1 1) Fig. 2 Block diagram of implantable drug delivery system with wireless communications and power transfer In practice, what this means is that a square cavity etched into silicon with a (1 0 0) surface will have sidewalls with an angle of 54.748 to the surface. This is illustrated in Fig. 3f .
A number of different etchants produce this type of silicon profile, and tetramethyl ammonium hydroxide [TMAH, (CH 3 ) 4 NOH) [16, 17] has been selected for this work, as it is compatible with CMOS technology [18] . It has the further advantages that it can be mixed with other chemicals to prevent it etching aluminium interconnect [19] and that it is less toxic than most other anisotropic etch solutions, such as alkaline metal hydroxides.
The etch solution used was 22% TMAH in water, heated to 908C, providing a ,100. etch rate of 40 mm min
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. The relatively high concentration and temperature give an even etch, without hillocking [17] , while still stopping on the membrane of silicon dioxide and nitride upon which the gold electrode is fabricated.
The dimensions of cavities produced by TMAH etching of (1 0 0) silicon depend on the thickness of the wafer and the desired size of the small hole on the front side. 
cavities, the pitch is 600 mm, which limits the packing density of cavities on the chip. An alternative would be to use the Bosch process to produce high aspect ratio cavities with vertical sidewalls. This provides a huge increase in the packing density of the reservoirs, enabling many hundreds of doses to be placed on a chip ,5 mm square. However, a 50 mm square, vertical-walled cavity in a 385 mm thick wafer has a volume of just under 1 nl. The key to this approach is to find a drug that can be sufficiently concentrated to be useful in such a tiny dosage.
Drug release membranes
There are two different approaches to fabricate the gold electrodes that will ultimately become the seal over the drug reservoir. In one process, the gold is deposited on the wafer before TMAH etching and covered with a passivation layer to protect it during subsequent steps. Alternatively, the cavities can be etched first, before the gold is deposited and patterned on the dielectric membrane covering the cavity opening. Each architecture has advantages and potential issues, but it was decided that depositing the gold before wet etching (as shown in Fig. 3 ) was preferable. This avoids the need for processing on the thin dielectric membrane and allows the gold to be protected by a thick Parylene layer during the wet etch.
In either case, the final stages of processing are to remove the dielectric membrane separating the gold from the cavity (Fig. 3g) and to pattern the passivation over the gold (Fig. 3h) . The dielectric membrane, which consists of a thin, low stress, bilayer of thermal silicon dioxide and low pressure stoichiometric silicon nitride, is removed from the cavity side by a reactive ion etch process. The passivation layer is a vapour-deposited organic polymer, Parylene C, (trade name for a group of para-xylene-based polymers deposited under vacuum at room temperature [20] ) which forms a conformal coating over the gold and is biocompatible [21 -23] . Parylene is extremely chemically resistance, but can be etched at up to 220 nm/min in an oxygen plasma [24] . Fig. 4 shows a gold cap after it has been released from the top passivation and the dielectric membrane.
The nominal thickness of the gold cap is 300 nm, which should be capable of withstanding a pressure of up to 60 psi [25] .
Filling and sealing
A number of different methods have been considered for the filling of micromachined cavities with a drug solution and thereafter sealing them. The original plan was to use an inkjet system, normally used to spot liquids onto microscope slides for DNA arrays, but it was felt that this was unnecessary for these prototype samples that had only a small number of cavities. A manual system using a drawn glass capillary tube allowed the filling of individual cavities without spreading the liquid between the reservoirs. Unfortunately, this typically led to air being sealed into the cavities, as the liquid evaporated quickly before the seal could be put in place.
The seal itself is an additional challenge. A number of different adhesives, including cyanoacrylates, UV curing epoxies and polydimethylsiloxane elastomer (PDMS), were used to bond glass cover slips over the cavities. This was partially successful, but had problems in that the adhesives tended to be hydrophilic and attracted the liquid out of the cavities, leading to a poor seal.
A practical filling technique using a low-tack, waterproof, adhesive tape was finally established as the preferred approach. The cavities are overfilled before the tape is applied. Force is then applied to squeeze out the excess liquid and fix the tape to the silicon surface. Fig. 5 shows the result of sealing liquid into an array of micromachined cavities. It should be noted that the tape only serves to seal the cavities until the chips are packaged. During packaging, the chips are encapsulated with a solid epoxy that immobilises the device to the package surface and should prevent any leakage from the cavities. However, it is likely that a more permanent seal would be required in a device intended for long-term or permanent implantation.
Control system
Test structures consisting of arrays of gold electrodes were fabricated to characterise the voltage levels required to open the drug reservoirs. This established that the voltage required for the reaction without a reference electrode was greater than the figure reported in [11] . A square wave, 1 Hz, signal stepping between 0 and þ3 V was applied between an anode and nearby cathode, and the resulting current flow is presented in Fig. 6 . This stripped the exposed area of the anode in ,30 s, which was confirmed both by observation of the electrode and by the reduction in the current drawn between 25 and 30 s of operation. Prototype chip A prototype device was designed with 12, TMAH-etched, cavities that can be individually addressed and the layout is shown in Fig. 7 . It has 14 bond pads, one for each anode cap, and two separate cathode connections.
In vitro packaging
This 3 Â 3 mm chip was designed for in vivo testing where it could be packaged into a system no larger than 5 Â 5 Â 5 mm. However, for initial in vitro testing, the chip was packaged into a standard dual-in-line (DIL) package, as illustrated in Fig. 8 .
Once the chip was glued in place and the electrical bonds were made to the package with gold wire, a thick, UV curing epoxy was applied. This protected the wires while leaving the front of the chip exposed. The plastic ring was glued in place to provide a reservoir for the saline electrolyte used in testing.
In vivo packaging
There is no suitable standard IC package available and so the packaging for in vivo devices used a custom, doublesided printed circuit board (PCB) (Fig. 9a) , 5 mm square, onto which the prototype chip was attached. The PCB has gold-coated tracks, suitable for wire bonding between it and the chip. Connections from the PCB to the outside world were made using 100 mm diameter, Teflon-coated, platinum wires. An example of a packaged in vivo device is shown in Fig. 9b . As with the DIL package, the wire bonds and other electrical connections are covered with a UV-cured epoxy. It is also possible to use this material to cover any cavities damaged during processing (a repaired cavity is shown in Fig. 9b ).
Drug release testing
Prototype chips were filled with a 20% solution of fluorescein sodium: a yellow/green fluorescent dye commonly used as a diagnostic aid in ophthalmology [26] . The filled chips were packaged as described earlier and a portable control system was used to activate and open individual cavities. This control box (Fig. 10) was custom built for testing these devices, containing a 9 V battery and the electronics required to generate the correct square wave voltage signal. A switch on the side of the box allowed the user to choose any one of the 12 cavities on the chip under test.
In vitro testing
8.1.1 Wired: In vitro testing was performed using a 10% solution of PBS as the electrolyte. The images in Fig. 11 show that fluorescein release begins within 5 s of activation and continues for some time afterwards. If the voltage supplied to the cell is a 3 V square wave with a 66% duty cycle, and the current that flows while the voltage is high is no .30 mA, the energy required to open the reservoir in 5 s is 300 mJ, with a maximum power of 90 mW. Fig. 12 shows the architecture of a wireless power transfer and communications system designed to be used with the prototype drug release chips. It operates by near-field inductive coupling between two resonant LC tanks. The transmission side includes a keypad controlling a Dual-Tone MultiFrequency (DTMF) encoder similar to that used in touch-tone telephones. The output of the DTMF encoder is used to modulate the RF power signal. On the receiver, side part of the circuit decodes the information, whereas the other part turns the RF power into the correct square wave voltage signal required to open a cavity. The decoded DTMF information controls a demultiplexer that directs the square wave voltage to the correct anode electrode on the drug release chip. This means that any one of the 12 cavities can be selected and opened by pressing the correct key on the transmitter side keypad. The system operates at a frequency of 7.1 MHz and is capable of transmitting over 500 mW of power over a distance of 30 mm using 0.1 M PBS as a transmission medium. The receiver system requires 370 mW of power to operate, including the 90 mW required to open a cavity, and the transmitter is certainly capable of supplying this. Further details of the RF power and communication system, including results of transmitting power to a receiver implanted into an ex vivo animal eye model, are presented in [27, 28] .
Wireless:
In vivo testing
A prototype device similar to that shown in Fig. 9 has been implanted temporarily into the eye of a rabbit. This was successfully activated and the release of fluorescein was observed externally through the cornea. The fluorescein was visible 5 min after activation and diffused through the whole of the vitreous cavity of the rabbit eye within 1 h.
Discussion and conclusions
An active, low-power MEMS drug delivery system, intended for ophthalmic applications, has been described. It comprises an MEMS drug release device, control circuitry and a wireless power and communications system. It operates by using an electrochemical reaction to remove a gold cap that seals a reservoir containing a dose of a drug. Although the release method is well understood and is being commercialised by the original researchers, the system described here, using direct wireless power transfer and communications, has the potential to allow for a miniaturised implant. Without a battery and discrete electronics, which would require bulky encapsulation, the entire system can be contained in a package only a few millimetres across. This enables it to be implanted into a wider range of locations within the body, such as into the vitreous cavity of the eye where it could release drugs to control chronic diseases such as glaucoma. It should be noted that the PCB required for the interconnect and the epoxy resin covering the prototype dominates the device volume. Obviously, this volume will be considerably reduced in a fully engineered implantable package.
The fabrication process used to create the reservoirs, cap them with a gold electrode membrane and then fill and seal them has been described. Prototype devices were fabricated and tested using a fluorescent dye as the reservoir contents. The release of the dye has been demonstrated in vitro and the maximum power required is shown to be ,100 mW. Wireless powered drug release and in vivo results have also been described.
Future work is required to upgrade the packaging technology used, as well as to increase the density of the drug reservoirs. 
